Table 5. Treatment-related toxicity and dose modification.
| Sex (years of age) | CTCa grade 1–2 | CTC grade 3 | CTC grade 4 | Dose modification (%)b |
|---|---|---|---|---|
| m (42) | Headaches, nausea, fatigue | −25 | ||
| m (71) | Nausea, gum bleeding | −25 | ||
| f (41) | Exanthema | −50 | ||
| f (51) | Exanthema | −50 | ||
| m (62) | Constipation | Intestinal perforation | −100 | |
| m (67) | Arterial thromboembolism | −100 | ||
| m (61) | Suicide attempt | −100 |
a
Toxicity was graded according to common toxicity criteria (CTC; http://ctep.cancer.gov/reporti ng/ctc.html).
b
Modification of imatinib dose in terms of reduction of the initial dose of 400 mg bid. A dose reduction of 100% represents complete cessation of study treatment.